Probiotic shows promise for Parkinson's in small study

NCT ID NCT06487975

Completed Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a daily probiotic supplement called Bacillus subtilis can change certain gut bacteria and blood markers in people with Parkinson's disease. Twenty-six participants took either the probiotic or a placebo for a period. The goal was to see if the supplement is acceptable and affects biomarkers linked to Parkinson's, not to treat symptoms directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bacillus subtilis (a probiotic supplement)
What this could lead to: If the probiotic shows clear effects on gut or blood markers, it could point toward a new way to manage Parkinson's disease.
What could go wrong: This is a very small, early-stage study focused on biomarkers, not symptoms. The results may not lead to any treatment change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

NHS Lothian

Edinburgh, United Kingdom
Norwegian Centre for Movement Disorders, Stavanger University Hospital

Stavanger, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.